WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017189722) VACCINE DIRECTED TO INDUCTION OF IMMUNE RESPONSE TO PROTEIN AND GLYCOLIPID ANTIGENS OF BACTERIAL CELLS THROUGH INTERACTION OF CD40L/CD40 RECEPTOR AXIS WITH COMPLEX OF GLYCOLIPID/CD1D RECEPTOR IN NKT CELLS AND IN DENDRITIC CELLS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/189722 International Application No.: PCT/US2017/029631
Publication Date: 02.11.2017 International Filing Date: 26.04.2017
IPC:
A61K 39/02 (2006.01) ,A61K 31/70 (2006.01) ,A61K 38/16 (2006.01) ,A61P 37/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
Applicants: MICROVAX, LLC[US/US]; Mason Enterprise Center 70 Main Street, Suite 23 Warrenton, Virginia 20186, US
Inventors: DEISSEROTH, Albert B.; US
Agent: SNYDER, Glenn; US
FRANK, Jacob; US
Priority Data:
15/138,51126.04.2016US
Title (EN) VACCINE DIRECTED TO INDUCTION OF IMMUNE RESPONSE TO PROTEIN AND GLYCOLIPID ANTIGENS OF BACTERIAL CELLS THROUGH INTERACTION OF CD40L/CD40 RECEPTOR AXIS WITH COMPLEX OF GLYCOLIPID/CD1D RECEPTOR IN NKT CELLS AND IN DENDRITIC CELLS
(FR) VACCIN DIRIGÉ CONTRE L'INDUCTION D'UNE RÉPONSE IMMUNITAIRE À DES ANTIGÈNES PROTÉIQUES ET GLYCOLIPIDIQUES DE CELLULES BACTÉRIENNES PAR L'INTERACTION DE L'AXE DU RÉCEPTEUR CD40L/CD40 AVEC UN COMPLEXE DE RÉCEPTEUR GLYCOLIPIDIQUE/CD1D DANS DES CELLULES NKT ET DANS DES CELLULES DENDRITIQUES
Abstract:
(EN) A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the ?-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to ?-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive- i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.
(FR) La présente invention concerne une combinaison de constituants permettant de favoriser une réponse immunitaire innée et adaptative comprenant un vaccin contre TAA/ecdCD40L et un complexe entre le récepteur CD1d et un glycolipide de type alpha galactosyl céramide (AGCLGL), pour activer les cellules NKT et activer le récepteur CD40 sur les cellules dendritiques (DC) et augmenter le niveau de la réponse immunitaire adaptative au TAA induite par le vaccin contre TAA/ecdCD40L. Le résultat et l'avantage de l'utilisation du vaccin contre TAA/ecdCD40L et du complexe alpha-galactosylcéramide-CD1d (ou d'un antigène bactérien ou autre associé à l'alpha galactosylcéramide) pour stimuler la réponse immunitaire par l'intermédiaire de l'axe CD40L/CD40 sur des cellules dendritiques, est que l'amplitude de la stimulation est robuste et augmentée significativement plus que l'effet additif, c'est-à-dire de façon synergique en raison de l'interaction, la diaphonie et/ou la stimulation croisée de la voie glycolipide-CD1d et de la voie TAA/ecdCD40L. En conséquence, une réponse immunitaire puissante est induite contre des antigènes cibles lipidiques ainsi que des antigènes cibles protéiques.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)